Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;108(1):90-98.
doi: 10.1002/cpt.1809. Epub 2020 Mar 16.

Exposure-Response Assessment in Pediatric Drug Development Studies Submitted to the US Food and Drug Administration

Yifei Zhang  1 , Yaning Wang  2 , Mona Khurana  3 , Hari Cheryl Sachs  3 , Hao Zhu  2 , Gilbert J Burckart  2 , John Alexander  1 , Lynne P Yao  3 , Jian Wang  1
Affiliations

Exposure-Response Assessment in Pediatric Drug Development Studies Submitted to the US Food and Drug Administration

Yifei Zhang et al. Clin Pharmacol Ther. 2020 Jul.

Abstract

Exposure-response (E-R) modeling provides a quantitative tool to leverage adult data to support pediatric trial design and drug approval. The pediatric E-R studies submitted to US Food and Drug Administration (FDA) between 2007 and 2018 were surveyed in the context of various types of trial designs supporting drug approval in the pediatric population. The applications of E-R evaluation in pediatric drug development programs are mainly focused on three areas: (i) supporting pediatric extrapolation when the E-R relationships are similar between the pediatric and adult populations; (ii) dose selection to balance the risk-benefit profile based on the change in efficacy and safety response with different exposure levels; and (iii) approval of a new formulation, new dosing regimen, or new route of administration, where E-R evaluation helps quantify the change in clinical response between the old and new strategies. E-R modeling will continue to play an expanded role in pediatric drug development in the future.

PubMed Disclaimer

References

    1. Dunne, J. et al. Extrapolation of adult data and other data in pediatric drug-development programs. Pediatrics 128, e1242-e1249 (2011).
    1. Ogasawara, K., Breder, C.D., Lin, D.H. & Alexander, G.C. Exposure- and dose-response analyses in dose selection and labeling of FDA-approved biologics. Clin. Ther. 40, 95-102.e2 (2018).
    1. US Food and Drug Administration. Guidance for industry: exposure-response relationships-study design, data analysis, and regulatory applications <https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformat... (2003). Accessed September 12, 2019.
    1. FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource <https://www.ncbi.nlm.nih.gov/books/NBK326791/> (2017).
    1. US Food and Drug Administration. Guidance for industry: general clinical pharmacology considerations for neonatal studies for drugs and biological products <https://www.fda.gov/media/129532/download> (2019). Accessed September 12, 2019.

Substances

LinkOut - more resources